<?xml version="1.0" encoding="UTF-8" ?> 

<rss version="2.0"> 
<channel> 
<title>HemeOncLinx News</title> 
<link>http://www.mdlinx.com/HemeOncLinx/news.cfm/newspage/1/spec_id/17/subspec_id/0</link> 
<description></description> 
<language>en-us</language> 
<copyright>Copyright 2009 MDLinx, Inc.</copyright>










 



<item> 
<title><![CDATA[Bevacizumab in the treatment of breast cancer]]></title> 
<link>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2960972</link> 
<pubDate>11/25/2009</pubDate> 
<description><![CDATA[<b>Cancer Treatment Reviews</b>]]></description> 
<guid>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2960972</guid>
</item> 
 

<item> 
<title><![CDATA[Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: Results from a phase II prospective trial ]]></title> 
<link>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2955802</link> 
<pubDate>11/25/2009</pubDate> 
<description><![CDATA[<b>Journal of Clinical Oncology</b>]]></description> 
<guid>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2955802</guid>
</item> 
 

<item> 
<title><![CDATA[Beta-tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: A companion analysis of the TAX 324 trial ]]></title> 
<link>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2955800</link> 
<pubDate>11/25/2009</pubDate> 
<description><![CDATA[<b>Journal of Clinical Oncology</b>]]></description> 
<guid>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2955800</guid>
</item> 
 

<item> 
<title><![CDATA[Five-aminolevulinic acid for fluorescence-guided resection of recurrent malignant gliomas: A phase II study]]></title> 
<link>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2962100</link> 
<pubDate>11/25/2009</pubDate> 
<description><![CDATA[<b>Neurosurgery</b>]]></description> 
<guid>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2962100</guid>
</item> 
 

<item> 
<title><![CDATA[Investigation into the controversial association of Streptococcus gallolyticus with colorectal cancer and adenoma]]></title> 
<link>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2958463</link> 
<pubDate>11/25/2009</pubDate> 
<description><![CDATA[<b>BMC Cancer</b>]]></description> 
<guid>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2958463</guid>
</item> 


 

<item> 
<title><![CDATA[Is preoperative ultrasonography accurate in measuring tumor thickness and predicting the incidence of cervical metastasis in oral cancer?]]></title> 
<link>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2960475</link> 
<pubDate>11/25/2009</pubDate> 
<description><![CDATA[<b>Oral Oncology </b>]]></description> 
<guid>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2960475</guid>
</item> 
 

<item> 
<title><![CDATA[Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909 ]]></title> 
<link>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2955807</link> 
<pubDate>11/25/2009</pubDate> 
<description><![CDATA[<b>Journal of Clinical Oncology</b>]]></description> 
<guid>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2955807</guid>
</item> 
 

<item> 
<title><![CDATA[A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer]]></title> 
<link>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2957548</link> 
<pubDate>11/25/2009</pubDate> 
<description><![CDATA[<b>Cancer</b>]]></description> 
<guid>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2957548</guid>
</item> 
 

<item> 
<title><![CDATA[Neuroendocrine carcinomas arising in solid-organ transplant recipients: rare but aggressive malignancies]]></title> 
<link>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2957436</link> 
<pubDate>11/25/2009</pubDate> 
<description><![CDATA[<b>Oncology (Karger)</b>]]></description> 
<guid>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2957436</guid>
</item> 
 

<item> 
<title><![CDATA[Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study]]></title> 
<link>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2959918</link> 
<pubDate>11/25/2009</pubDate> 
<description><![CDATA[<b>Annals of Hematology</b>]]></description> 
<guid>http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2959918</guid>
</item> 
 
 


  


</channel> 
</rss>

